Categories | Inventors

pLXSN human KIT V654A + D816F


OHSU # 1658-D

Technology Overview:

Technology Overview
This line was created by ENU-mutagenesis of BaF3 pLXSN KIT D816F cell line and subsequent drug selection. The V654A mutation is associated with imatinib-resistance in GIST. This cell line expresses high levels of activated KIT. In addition to the engineered D816F mutation, the cells also acquired the following mutations due to retrovirus recombination events: I571M and M903I. These secondary events do not appear to alter the kinase properties of KIT or alter the pattern of KIT D816F sensitivity/resistance to kinase inhibitors. This cell line is strongly resistant to imatinib.



For more information, contact:

Trina Voss
Technology Development Manager

(terms)  $0.00
(terms)  $10000.00